Summary of biologically based strategies for HL
Mechanisms of action . | Examples of drugs/compounds . |
|---|---|
| Receptor-specific antibodies | |
| ADCC | CD30 antibody SGN-30 (Seattle Genetics) or MDX-60 (Medarex) |
| CD20 antibody rituximab (Roche) (mostly for LPHL) | |
| IL-13 antibody CAT-354 (Cambridge Antibody Technology) | |
| CD40 antibody CHIR-12.12 (Chiron Oncology) | |
| RANKL antibody AMG162 (Amgen) | |
| Proapoptotic | TRAIL-R1 antibody (Human Genome Sciences) |
| Protein-specific small molecules | |
| Inhibition of antiapoptotic pathways | Proteasome inhibitor bortezomib (PS-341; Millennium Pharmaceuticals) |
| IKKβ inhibitors SPC-839 (Celgene) or BMS-345541 (BMS) | |
| CDDO (RTA401; Reata Pharmaceuticals) | |
| XIAP antagonist Di/triphenylureas (1396-11,12,34) (The Burnham Institute/Torrey Pines Institute for Molecular Studies) | |
| Transcriptional modulation (HDAC inhibitors) | NFκB modulation by depsipeptide (FK228; Gloucester Pharmaceuticals) or suberoylanilide hydroxamic acid (SAHA; Aton Pharma) |
| Gene-specific antisense oligonucleotides | |
| Inhibition of antiapoptotic pathways | STAT3 antisense-molecule ISIS 345794 (ISIS Pharmaceuticals) |
| XIAP antisense-molecule AEG35156 (Aegera Therapeutics) | |
| Antigen-specific adoptive T-cell transfer | |
| Induction of cytotoxicity | Individual EBV-specific cytotoxic T cells |
Mechanisms of action . | Examples of drugs/compounds . |
|---|---|
| Receptor-specific antibodies | |
| ADCC | CD30 antibody SGN-30 (Seattle Genetics) or MDX-60 (Medarex) |
| CD20 antibody rituximab (Roche) (mostly for LPHL) | |
| IL-13 antibody CAT-354 (Cambridge Antibody Technology) | |
| CD40 antibody CHIR-12.12 (Chiron Oncology) | |
| RANKL antibody AMG162 (Amgen) | |
| Proapoptotic | TRAIL-R1 antibody (Human Genome Sciences) |
| Protein-specific small molecules | |
| Inhibition of antiapoptotic pathways | Proteasome inhibitor bortezomib (PS-341; Millennium Pharmaceuticals) |
| IKKβ inhibitors SPC-839 (Celgene) or BMS-345541 (BMS) | |
| CDDO (RTA401; Reata Pharmaceuticals) | |
| XIAP antagonist Di/triphenylureas (1396-11,12,34) (The Burnham Institute/Torrey Pines Institute for Molecular Studies) | |
| Transcriptional modulation (HDAC inhibitors) | NFκB modulation by depsipeptide (FK228; Gloucester Pharmaceuticals) or suberoylanilide hydroxamic acid (SAHA; Aton Pharma) |
| Gene-specific antisense oligonucleotides | |
| Inhibition of antiapoptotic pathways | STAT3 antisense-molecule ISIS 345794 (ISIS Pharmaceuticals) |
| XIAP antisense-molecule AEG35156 (Aegera Therapeutics) | |
| Antigen-specific adoptive T-cell transfer | |
| Induction of cytotoxicity | Individual EBV-specific cytotoxic T cells |
ADCC indicates antibody-dependent cellular cytotoxicity; HDAC, histone deacetylase.
Locations for manufacturers are as follows: Seattle Genetics, Bothell, WA; Medarex, Princeton, NJ; Roche, Milan, Italy; Cambridge Antibody Technology, Cambridge, United Kingdom; Chiron Oncology, Berkshire, United Kingdom; Amgen, Thousand Oaks, CA; Human Genome Sciences, Rockville, MD; Millennium Pharmaceuticals, Cambridge, MA; Celgene, Middlesex, United Kingdom; BMS (Bristol-Myers Squib), New York, NY; Reata Discovery, Dallas, TX; Gloucester Pharmaceuticals, Cambridge, MA; Aton Pharma, Tarrytown, NY; ISIS Pharmaceuticals, Carlsbad, CA; and Aegera Therapeutics, Montreal, QC.